title: Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.
abstract: OBJECTIVE
  Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment.
  
  
  METHODS
  We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers.
  
  
  RESULTS
  Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate.
  
  
  CONCLUSIONS
  Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.
authors.affiliation: Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, žemsi Denizer Cad. E-5 Karayolu Cevizli Mevkii, 34890, Kartal/Istanbul, Turkey. taner.korkmaz@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Korkmaz
authors.forename: S
authors.initials: S
authors.lastname: Seber
authors.forename: U
authors.initials: U
authors.lastname: Kefeli
authors.forename: E
authors.initials: E
authors.lastname: Sari
authors.forename: M
authors.initials: M
authors.lastname: Canhoroz
authors.forename: B
authors.initials: B
authors.lastname: Oven
authors.forename: E
authors.initials: E
authors.lastname: Yildirim
authors.forename: N
authors.initials: N
authors.lastname: Yasar
authors.forename: D
authors.initials: D
authors.lastname: Aydin
authors.forename: O
authors.initials: O
authors.lastname: Balvan
authors.forename: N
authors.initials: N
authors.lastname: Sener
authors.forename: S
authors.initials: S
authors.lastname: Yuksel
authors.forename: A
authors.initials: A
authors.lastname: Mert
authors.forename: O
authors.initials: O
authors.lastname: Polat
authors.forename: F
authors.initials: F
authors.lastname: Yumuk
authors.forename: O
authors.initials: O
authors.lastname: Kanat
authors.forename: M
authors.initials: M
authors.lastname: Gumus
authors.forename: N S
authors.initials: NS
authors.lastname: Turhal
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin